Advanced or Metastatic ER+ HER2- Breast Cancer (mBC)
Oncology·MeSH: Carcinoma, Non-Small-Cell Lung
Prevalence
287.0 / 100K
Incidence
128.0 / 100K/yr
4 drugs in development·1 company·1 clinical trial
Drug Pipeline by Phase
Compare drugs
Frequently asked questions
How many drugs are in development for Advanced or Metastatic ER+ HER2- Breast Cancer (mBC)?
BioSniper tracks 4 drugs in development for Advanced or Metastatic ER+ HER2- Breast Cancer (mBC) across 1 company.
How many clinical trials target Advanced or Metastatic ER+ HER2- Breast Cancer (mBC)?
There are 1 clinical trial targeting Advanced or Metastatic ER+ HER2- Breast Cancer (mBC) tracked by BioSniper.
What is the prevalence of Advanced or Metastatic ER+ HER2- Breast Cancer (mBC)?
The estimated prevalence of Advanced or Metastatic ER+ HER2- Breast Cancer (mBC) is approximately 287.0 per 100,000 population.
Deep-dive into Advanced or Metastatic ER+ HER2- Breast Cancer (mBC)
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis